BRIEF-Janssen's Imbruvica receives CHMP opinion for use in lymphocytic leukaemia patients

* Janssen's Imbruvica (ibrutinib) receives positive CHMP opinion for expanded use in previously untreated chronic lymphocytic leukaemia patients
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.